PPN4 PATIENT SEGMENTATION AND DRIVERS OF ACCESS TO PATIENT CONTROLLED ANALGESIA  by Nuyts, G & Jones, MP
A168 Abstracts
pared to the $125 million in savings attributed to the Medi-Cal
equivalent NDCs, an additional $8 million could be gained if
repackaged pharmaceuticals were priced with a relevant Medi-
Cal rate such as an average Estimated Acquisition Cost, an
overall savings of 35.8%. On a per prescription basis, the prac-
tice of repackaging costs an additional $20 when compared to a
Medi-Cal pharmacy dispensed reimbursement rate. CONCLU-
SION: This study informs new legislation being proposed to stop
the generous pricing of repackaged pharmaceuticals due to non-
equivalent NDCs. For the ﬁrst time we describe the practice of
repackaging pharmaceuticals and identify cost savings expected
with alternative pricing systems, but also identify the value of
repackaging pharmaceuticals for WC patients.
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OBJECTIVES: Patient controlled analgesia (PCA) with pump
delivery is the mainstay of modern postoperative pain manage-
ment, with often better pain control compared to competing
methods. We performed a data mining study to identify the 
clinical and hospital infrastructure correlates of PCA use.
METHODS: Patients older than 18 years having major opera-
tive procedures expected to require strong opioid based post-
operative pain control were selected from the Premier Perspective
database. Obstetric patients were excluded. Two random
samples were selected: a training sample of N = 21,782 and a
validation sample of N = 21,538. Factor analysis mapped the 75
observed explanatory variables, not related to post-operative
pain method onto 17 independent factors. Patient segmentation
was performed based on cluster analysis. RESULTS: Thirteen
distinct clusters were identiﬁed each with distinguishing demo-
graphic, clinical, payor and hospital setting features. Percent of
PCA use in each of the segments ranged from 3% to 38%. Six
segments, accounting for 3.5%, 1.8%, 8.4%, 4.1%, 6.1% and
9.2% of the total population had PCA usage below 10%. Only
three segments had PCA usage more than 20% with 4.7%,
14.5% and 7.8% of the population. Qualitative evaluation indi-
cated that the primary factor determining whether a segment had
low or high PCA use was the circumstance of admission: for
urgent admissions PCA was lowest, while the highest PCA use
was observed in those segments characterized by elective admis-
sions. CONCLUSION: Use of PCA differs between segments in
a heterogeneous cohort of post-operative pain patients. That the
driver of this difference was admission source may suggest that
time required to prepare PCA is an important factor in its actual
use and that thus easier PCA methods may increase patient’s use
of PCA.
PAIN—Patient Reported Outcomes
PPN5
ADVANCES IN PAIN MEASUREMENT: ITEM RESPONSE
THEORY (IRT) BASED METHODS AND THE PAIN IMPACT
QUESTIONNAIRE (PIQ-6)
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OBJECTIVES: To use IRT-based methods to develop a six-item
questionnaire (PIQ-6) measuring pain severity and pain impact.
IRT was used to: 1) identify the most informative items from a
bank of 65 items, 2) evaluate construct validity, 3) norm the PIQ-
6 to the US general population; 4) cross-calibrate it to the SF-
36v2 BP scale; 5) develop a simple scoring approach based on
response category weights matching the IRT score; and 6) build
a computerized version to facilitate monitoring and management
of pain. METHODS: Items analyses and selection were based on
data from two web-based general population samples (n = 782,
n = 829) and a chronic pain patients sample (n = 306). Norming
was achieved by recalibrating the IRT-based item parameter
using 1998 US representative norm data of the SF36v2 (n =
7069). Cross-calibration of the PIQ-6 and SF-36v2 was per-
formed by estimating the expected SF-36v2 BP scale score using
IRT-based item parameter. The PIQ-6 computerized version was
programmed with Microsoft Visual Basic. RESULTS: Six items
were identiﬁed that ﬁtted an unidimensional IRT model, showed
high measurement precision and did not show differential item
functioning. Construct validity was supported by high correla-
tions with other pain measures and strong discrimination of pain
patients and the general population. The PIQ-6 is normed so that
a score of 50 represents the US general population norm (sd =
10). A cross-calibration table of the PIQ-6/SF-36v2 was created
to facilitate communication between researchers using those 
different instruments. The simple hand scoring approach had 
satisfactory agreement with the IRT scores. The PIQ-6 was 
programmed as computerized stand-alone/PDA/online versions
allowing for an easy administration, scoring and immediate feed-
back reporting including interpretation guidelines. CONCLU-
SIONS: Pain measurement can be improved by using IRT and
computerized methods. Noteworthy advantages of the PIQ-6 are
the enhancement of measurement precision and coverage as well
as the facilitation of monitoring and managing pain.
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DATABASE ANALYSIS
Kochevar JJ1,Williams TD1
1Kochevar Research Associates, Boston MA, USA
OBJECTIVES: Our objective was to examine results of different
calculation methods for compliance, persistence and medication
gaps using prescription reﬁll claims. METHODS: This was a ret-
rospective analysis of statin prescription claims in the Protocare
database from 1/1/96 to 12/31/02. Statistics were based on ﬁrst-
time statin users (no statin claims in last year) continuously
enrolled for a minimum of 2.5 years after their ﬁrst statin claim
(N = 45,754) and up to a maximum of 6 years. Compliance was
calculated as the “simple” medical possession ratio (MPR)—
days supply/ 365 days—and as “adjusted” MPR, systematically
accounting for gaps and surplus days supply. Persistence was cal-
culated as “continuous” statin persistence (no gap in supply
greater than 30 days) and as “any” statin supply per one year
periods. Gaps were calculated for number of gaps of one day or
more without days supply and average gap length in 365 days.
RESULTS: “Simple” MPR in the ﬁrst year of use was 62% (S.D.
= 0.36). For the same period “adjusted” MPR was 59% (S.D.
0.33) and lower for 50% of the sample. The average difference
was 0.04 (14.6 days). Approximately 34% of the sample was
continuously persistent thru year 1, falling to 21% in year 2;
however, 73 percent had at least one prescription in year 2. Com-
pliance, persistence and gaps varied year by year over patient’s
total coverage periods. CONCLUSIONS: Failure to account 
for gaps and cumulative surpluses in prescription reﬁlls can
distort compliance estimates. “Any” persistence statistics indi-
cate that a higher proportion of statin users remain intermittent
rather than discontinued over long periods of time. Statistics on
number and length of gaps are necessary to provide a full
